製品番号: HY-W041315

CFL-120

カスタマーレビュー

Based on 1 Customer Validation

CFL-120 is a potent KRas^G12C inhibitor. CFL-120 shows an antiproliferative effect. CFL-120 shows anticancer activity. CFL-120 has the potential for the research of lung cancer.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

純度: 98.0%
CAS 番号: 18711-15-4
分子式: C₈H₃Cl₂NO₂
分子量:216.02

保管条件:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

CFL-120 構造式

CAS 番号: 18711-15-4

容量

価格（税別）

在庫状況

数量

Amount: USD 0.00

* アイテムを追加する前、数量をご選択ください

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

生物活性
- 製品説明
- IC₅₀ & Target
- Cellular Effect
- 体外実験
- 体内実験
化学情報
溶剤 & 溶解度
- 体外
純度とドキュメンテーション
参考文献
Help & FAQs
関連分類
Bioz

生物活性

製品説明

CFL-120 is a potent KRas^G12C inhibitor. CFL-120 shows an antiproliferative effect. CFL-120 shows anticancer activity. CFL-120 has the potential for the research of lung cancer^[1].

IC₅₀ & Target^[1]

KRAS(G12C)

Ras アイソフォーム固有の製品をすべて表示 :

Cellular Effect

Cell Line	Type	Value	Description	References
A549	IC₅₀	44.4 μM Compound: CFL-120	Antiproliferative activity against human A549 cells harboring homozygous KRAS G12S mutant assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human A549 cells harboring homozygous KRAS G12S mutant assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 36842271]
BXPC-3	IC₅₀	13.1 μM Compound: CFL-120	Antiproliferative activity against human BXPC-3 cells harboring wild type KRAS assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human BXPC-3 cells harboring wild type KRAS assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 36842271]
HUVEC	IC₅₀	24.4 μM Compound: CFL-120	Cytotoxicity against HUVEC cells immortalized with TERT assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Cytotoxicity against HUVEC cells immortalized with TERT assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 36842271]
LCLC-103H cell line	IC₅₀	30 μM Compound: CFL-120	Antiproliferative activity against human LCLC-103H cells harboring wild type KRAS assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human LCLC-103H cells harboring wild type KRAS assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 36842271]
MIA PaCa-2	IC₅₀	13.7 μM Compound: CFL-120	Antiproliferative activity against human MIA PaCa-2 cells harboring homozygous KRAS G12C mutant assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human MIA PaCa-2 cells harboring homozygous KRAS G12C mutant assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 36842271]
MRC5	IC₅₀	47.9 μM Compound: CFL-120	Cytotoxicity against human MRC5 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Cytotoxicity against human MRC5 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 36842271]
NCI-H1792	IC₅₀	11 μM Compound: CFL-120	Antiproliferative activity against human NCI-H1792 cells harboring heterozygous KRAS G12C mutant assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human NCI-H1792 cells harboring heterozygous KRAS G12C mutant assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 36842271]
NCI-H358	IC₅₀	16.9 μM Compound: CFL-120	Antiproliferative activity against human NCI-H358 cells harboring heterozygous KRAS G12C mutant assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human NCI-H358 cells harboring heterozygous KRAS G12C mutant assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 36842271]
PANC-1	IC₅₀	38 μM Compound: CFL-120	Antiproliferative activity against human PANC-1 cells harboring heterozygous KRAS G12D mutant assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human PANC-1 cells harboring heterozygous KRAS G12D mutant assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 36842271]
SW1573	IC₅₀	23.6 μM Compound: CFL-120	Antiproliferative activity against human SW1573 cells harboring homozygous KRAS G12C mutant assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human SW1573 cells harboring homozygous KRAS G12C mutant assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 36842271]
SW480	IC₅₀	14.8 μM Compound: CFL-120	Antiproliferative activity against human SW480 cells harboring homozygous KRAS G12V mutant assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human SW480 cells harboring homozygous KRAS G12V mutant assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 36842271]

体外実験

CFL-120 (72 h) shows an antiproliferative effect with IC₅₀s of 11.0, 23.6, 13.7, 16.9, 44.4, 14.8, 38.0, 30.0, 13.1, 9.8, 47.9, 24.4, 42.7 µM for H1792, SW1573, MiaPaca2, H358, A549, SW480, PANC-1, LCLC-103H, BxPC3, HCA-7, MRC-5, HUVEC-TERT, CCD-986Sk cells, respectively^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

体内実験

CFL-120 (5 mg/kg, 5 treatments; 15 mg/kg, 5 treatments; 30 mg/kg, 3 treatments; i.p.) reduces tumor growth in subcutaneous H1792 (KRasG12C mutant) and LCLC-103H (KRasWT) human lung cancer-bearing mice^[1].
Pharmacokinetic Parameters of CFL-120 in NOD-SCID female mice^[1].

PK parameters	CFL-137
C_max (ng/mL)	337 ± 123
T_max (h)	0.25
AUC_t (ng/mL*h)	169 ± 56
t_1/2 (h)	4.4 ± 0.6
V_d (mL)	12,096 ± 4000
CL(mL/h)	1895 ± 539

NOD-SCID female mice, 15 mg/kg IP^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

NOD/SCID female mice (KRasWT (LCLC-103H) or KRasG12C (H1792) tumors)^[1]
Dosage:

5 mg/kg, 5 treatments; 15 mg/kg, 5 treatments; 30 mg/kg, 3 treatments
Administration:

I.p.
Result:

Reduced tumor growth compared to the control group in KRasG12C mutated model for 35.8%.

化学情報

CAS 番号 18711-15-4
性状 Solid
分子量 216.02
分子式 C₈H₃Cl₂NO₂
Color Light yellow to yellow
SMILES

C1=C(C=C(C2=C1NC(C2=O)=O)Cl)Cl
輸送条件

Room temperature in continental US; may vary elsewhere.

保管条件

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

溶剤 & 溶解度

体外:

DMSO : 100 mg/mL (462.92 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

4.6292 mL

23.1460 mL

46.2920 mL

5 mM

0.9258 mL

4.6292 mL

9.2584 mL

10 mM

0.4629 mL

2.3146 mL

4.6292 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

モル濃度計算機

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

濃度濃度

体積体積

分子量分子量

希釈計算機

濃度 _(開始) × 体積 _(開始) = 濃度 _(終了) × 体積 _(終了)

濃度 _(開始) 濃度 _(開始)

体積 _(開始) 体積 _(開始)

濃度 _(終了) 濃度 _(終了)

体積 _(終了) 体積 _(終了)

純度とドキュメンテーション

バッチを選択:

純度: 99.98%

Assay: 99.98%

ee.: 99.98%

データシート (275 KB)
SDS (480 KB)
- English - EN (480 KB)
- Français - FR (480 KB)
- Deutsch - DE (480 KB)
- Norwegian - NO (480 KB)
- Español - ES (480 KB)
- Swedish - SV (480 KB)
- Italian - IT (480 KB)
- Korean - KR (480 KB)
- Portuguese - PT (480 KB)
COA (2659 KB)
元素分析報告書 (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
取扱説明書 (2659 KB)

参考文献

[1]. Orgován Z, et al. Covalent fragment mapping of KRasG12C revealed novel chemotypes with in vivo potency. Eur J Med Chem. 2023 Mar 15;250:115212. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	4.6292 mL	23.1460 mL	46.2920 mL	115.7300 mL
	5 mM	0.9258 mL	4.6292 mL	9.2584 mL	23.1460 mL
	10 mM	0.4629 mL	2.3146 mL	4.6292 mL	11.5730 mL
	15 mM	0.3086 mL	1.5431 mL	3.0861 mL	7.7153 mL
	20 mM	0.2315 mL	1.1573 mL	2.3146 mL	5.7865 mL
	25 mM	0.1852 mL	0.9258 mL	1.8517 mL	4.6292 mL
	30 mM	0.1543 mL	0.7715 mL	1.5431 mL	3.8577 mL
	40 mM	0.1157 mL	0.5787 mL	1.1573 mL	2.8933 mL
	50 mM	0.0926 mL	0.4629 mL	0.9258 mL	2.3146 mL
	60 mM	0.0772 mL	0.3858 mL	0.7715 mL	1.9288 mL
	80 mM	0.0579 mL	0.2893 mL	0.5787 mL	1.4466 mL
	100 mM	0.0463 mL	0.2315 mL	0.4629 mL	1.1573 mL

Keywords

製品名:
製品番号:
数量:
日本の代理先をお選びください:

製品名:
CAS 番号:
生物種:
純度:
数量:

CFL-120

Structurally Diverse Fragment Library

MCE Kinase Hinge Binder Fragment Library

Covalent Fragment Library

Multifunctional Covalent Fragment Library

Ras アイソフォーム固有の製品をすべて表示

生物活性

化学情報

溶剤 & 溶解度

純度とドキュメンテーション

参考文献

Help & FAQs

Complete Stock Solution Preparation Table

CFL-120

Structurally Diverse Fragment Library

MCE Kinase Hinge Binder Fragment Library

Covalent Fragment Library

Multifunctional Covalent Fragment Library

Ras アイソフォーム固有の製品をすべて表示

生物活性

化学情報

溶剤 & 溶解度

純度とドキュメンテーション

参考文献

Help & FAQs

Complete Stock Solution Preparation Table

CFL-120 関連分類

HY-W041315 関連分類